MAPK8 and neoplasm: - Although significant headway has been made in improving the specificity and selectively of ATP-competitive and substrate-competitive JNK inhibitors, these compounds and peptides are unlikely to yield clinical success as anti-cancer therapies due to their indiscriminate inhibitory effects on the physiological and tumor-suppressing functions of JNK.